Loading...
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
Basu, B Krebs, Matthew G Sundar, R Wilson, R Spicer, J Jones, R Brada, M Talbot, D Steele, N Ingles Garces, A
Basu, B
Krebs, Matthew G
Sundar, R
Wilson, R
Spicer, J
Jones, R
Brada, M
Talbot, D
Steele, N
Ingles Garces, A
Citations
Altmetric:
Abstract
We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients.
Authors
Basu, B
Krebs, Matthew G
Sundar, R
Wilson, R
Spicer, J
Jones, R
Brada, M
Talbot, D
Steele, N
Ingles Garces, A
Brugger, W
Harrington, E
Evans, J
Hall, E
Tovey, H
de Oliveira, F
Carreira, S
Swales, K
Ruddle, R
Raynaud, F
Purchase, B
Dawes, J
Parmar, M
Turner, A
Tunariu, N
Banerjee, S
de Bono, J
Banerji, U
Krebs, Matthew G
Sundar, R
Wilson, R
Spicer, J
Jones, R
Brada, M
Talbot, D
Steele, N
Ingles Garces, A
Brugger, W
Harrington, E
Evans, J
Hall, E
Tovey, H
de Oliveira, F
Carreira, S
Swales, K
Ruddle, R
Raynaud, F
Purchase, B
Dawes, J
Parmar, M
Turner, A
Tunariu, N
Banerjee, S
de Bono, J
Banerji, U
Description
Date
2018-07-17
Publisher
Collections
Files
Keywords
Type
Article
Citation
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. 2018, Ann Oncol